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Abstract
Rationale Problematic patterns of gambling are characterised by loss of control and persistent gambling often to recover losses.
However, little is known about the mechanisms that mediate initial choices to begin gambling and then continue to gamble in the
face of losing outcomes.
Objectives These experiments first assessed gambling and loss-chasing performance under different win/lose probabilities in
C57Bl/6 mice, and then investigated the effects of antagonism of 5-HT2CRwith SB242084, 5-HT1AR agonismwith 8-OH-DPAT
and modafinil, a putative cognitive enhancer.
Results As seen in humans and other species, mice demonstrated the expected patterns of behaviour as the odds for winning were
altered increasing gambling and loss-chasing when winning was more likely. SB242084 decreased the likelihood to initially
gamble, but had no effects on subsequent gambling choices in the face of repeated losses. In contrast, 8-OH-DPAT had no effects
on choosing to gamble in the first place, but once started 8-OH-DPAT increased gambling choices in a dose-sensitive manner.
Modafinil effects were different to the serotonergic drugs in both decreasing the propensity to initiate gambling and chase losses.
Conclusions We present evidence for dissociable effects of systemic drug administration on different aspects of gambling
behaviour. These data extend and reinforce the importance of serotonergic mechanisms in mediating discrete components of
gambling behaviour. They further demonstrate the ability of modafinil to reduce gambling behaviour. Our work using a novel
mouse paradigm may be of utility in modelling the complex psychological and neurobiological underpinnings of gambling
problems, including the analysis of genetic and environmental factors.
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Introduction
With increased access to opportunities to gamble in society, on
the high street or via social media, more people are gambling
these days than ever before. For most people, gambling is
something that they can dip into occasionally and easily con-
trol, but for others, gambling can become a major problem
affecting work and home life, personal relationships and fi-
nancial security (Gainsbury 2015). Efforts to understand path-
ological gambling reveal a complex mix of genetic, familial
and environmental risk factors, the former including gene var-
iants that influence monoaminergic systems (Hodgins et al.
2011) and the latter socio-economic status, education, gender
and accessibility to gambling platforms (van den Bos et al.
2013; Gainsbury 2015). Gambling problems are mediated by
altered neuromodulation within mesolimbic reinforcement
sites and altered neural responses to monetary rewards and
gambling-related cues (Zack and Poulos 2004; Chase and
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Clark 2010; Balodis et al. 2012; Worhunsky et al. 2014).
These dysfunctional brain responses may mediate the altered
cognitions that promote gambling and, in vulnerable individ-
uals, gambling problems (Campbell-Meiklejohn et al. 2008;
Clark et al. 2009; Clark 2010). Current treatments include
cognitive and/or behavioural therapies (Stea and Hodgins
2011) but also a variety of pharmacological options including
SSRIs, mood stabilisers, atypical anti-psychotics and opioid
antagonists (Grant et al. 2014). These therapies have uncertain
efficacy, especially over the longer term, and there remains a
need to better understand the neurobiology and risk factors
associated with gambling behaviours and problematic gam-
bling in order to identify more effective interventions and
therapeutic targets (Potenza et al. 2013; Gainsbury 2015).
The progression from recreational gambling to pathologi-
cal gambling is thought to be due to the loss of control and
development of the characteristic loss-chasing behaviour
(Lesieur 1979; Breen and Zuckerman 1999). Loss-chasing is
the tendency to continue gambling or escalate stakes in the
face of successive and accumulating losses (mainly financial)
and may occur within a single session or over the longer
term—both with the ultimate aim to ‘get even’ (Lesieur
1977, 1979). Between-session loss-chasing occurs, as the
name suggests, over a longer period of time and may include
multiple gambling sessions (Lesieur 1977). The majority of
research has investigated within-session loss-chasing, where
an individual attempts to recoup losses within a single session
(Parke et al. 2016). Behavioural economic perspectives attri-
bute loss-chasing to a convex function linking accumulating
monetary losses to only diminishing marginal reductions in
subjective value or utility, promoting further risk-seeking
choices (Kahneman and Tversky 1979; Kahneman and
Tversky 2000). However, in clinical populations, loss-
chasing is markedly exaggerated and is associated with
heightened trait impulsivity and erroneous false beliefs that
support continued play (Breen and Zuckerman 1999). Loss-
chasing is also associated with alcohol use and its
disinhibitory effects (O'Connor and Dickerson 2003) and
can be increased by alcohol consumption (Kyngdon and
Dickerson 1999). These behavioural features make loss of
control and consequent loss-chasing a key mechanism by
which problem gambling produces its adverse financial, oc-
cupational and social consequences (Lesieur 1979).
There have been limited previous studies of the pharmaco-
logical basis of within-session loss-chasing. Using an experi-
mental model in which human volunteers chose between gam-
bling to recover accumulating (notional) losses by doubling
their stakes or ‘quitting the chase’, Campbell-Meiklejohn and
colleagues (Campbell-Meiklejohn et al. 2008, 2011) demon-
strated that loss-chasing involves dissociable roles for mono-
amine systems, with serotonin activity modulating the persis-
tence of chasing behaviour, but dopamine and, in particular,
D2/D3 receptor (R) activity modulating the evaluation of
losses worth chasing (Campbell-Meiklejohn et al. 2011,
2012; Rogers 2011). Exploiting the foraging preference of
animals to access food promptly (Bateson and Kacelnik
1995; Kacelnik and Bateson 1996), Rogers et al. (2013) using
rats modelled within-session loss-chasing as choices between
immediate food access versus delayed access to food rewards
(timeouts) over successive bad choice outcomes. With accu-
mulating increases in delay to receiving reward as the penalty
for continued gambling (and losing), whereas as quitting gam-
bling would bring about reward sooner. Consistent with the
human data (Campbell-Meiklejohn et al. 2011, 2012), the 5-
HT1AR agonist 8-OH-DPAT and D2R antagonist eticlopride,
diminished loss-chasing behaviour, increasing quitting at the
first opportunity, whilst the D1R antagonist, SCH23390, had
little effect (Rogers et al. 2013).
Both behavioural economic arguments and also the
possibility that loss-chasing may be supported by behav-
ioural momentum effects (defined as the persistence of
gambling choices on the basis of previous winning
outcomes/rewards in the same context) raise the possibil-
ity that different mechanisms mediate the commencement
of gamble choices and their persistence. One hypothesis
here, maybe the allocation of behavioural control of rein-
forcement learning balanced between model-based and
mode-free systems, the former centred in prefrontal corti-
cal regions and the latter in striatal regions of the brain.
Complex or demanding situations may transition process-
ing from the inflexible model-free system to the more
flexible goal-directed model-based processing system
(Daw et al. 2005; Russek et al. 2017; Kim et al. 2019).
In terms of gambling and loss-chasing, then these systems
could relate to the habitual nature of gambling (model-
free), and the goal-directed actions underlying loss-
chasing (model-based). Here, we investigate this dissoci-
ation using an adapted model of within-session loss-chas-
ing for mice and use specific drug challenges to demon-
strate novel pharmacological dissociations between the
initial decision to gamble (to avoid timeouts and gain
immediate palatable condensed milk rewards) and succes-
sive choices over pre-programmed sequences of losing
outcomes.
Our data provide evidence consistent with the existence of
neurobiologically distinct mechanisms underlying gambling
and loss-chasing behaviour based on serotonergic signalling,
via 5-HT2CR and 5-HT1AR mechanisms and also, for the first
time in an animal model, the administration of the putative
‘cognition enhancer’ modafinil, which may have therapeutic
potential in pathological gambling (Łabuzek et al. 2014;
Pettorruso et al. 2014). In using mice in these studies, we also
further demonstrate the tractability of this species in investi-
gating complex behaviour and provide a new platform that
can be used for the pharmacological or genetic investigation
of gambling behaviours.
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Methods and materials
Subjects
Two cohorts of male C57Bl/6OlaHsd mice (Envigo, UK)
(N = 20/cohort), 3 months old at the start of the experiment,
were housed in groups of four, in a vivarium (temperature: 21
± 2 °C, humidity 50% ± 10) and a 12:12 light/dark cycle
(lights on at 07:00 h). Food was available ad libitum; follow-
ing 2 weeks of habituation and handling, the mice were placed
on a home cage water restriction schedule of 2 h access/day,
maintained for the duration of the experiment to motivate the
animals to work in the task. Animals were treated in accor-
dance with the Animal (Scientific Procedures) Act (United
Kingdom, 1986).
Apparatus
The gambling/loss-chasing task (G/LCT) was performed in
four mouse touchscreen chambers (Campden Cognition,
UK, and see Bussey et al. 2012), under the control of custom
written software (ABET, Campden Cognition, UK).
Touchscreens were occluded by black Perspex masks with
three 70 mm square response apertures 20 mm from the grid
base of the chamber and positioned equally across the width of
the mask. In the opposite side of the chamber, 5 mm from the
grid base, was a 20 mm square recess (25 mm deep) from
which liquid reward was delivered. Infra-red beams were used
to record motor activity.
Procedure
Following 2 weeks home cage water restriction schedule, the
mice were habituated to the liquid reward of 10% condensed
milk (Nestle Ltd., UK) solution (Humby et al. 1999, 2005).
Subjects were habituated to the touchscreen chambers for
3 days and then trained to make a response to the central
touchscreen stimulus location to earn reward (see
Supplementary Methods Figure 1. When mice showed stable
responding (> 40 responses/session for two consecutive ses-
sions), the G/LCT was commenced with an initial training
baseline version of the task in which touch responses to the
gamble stimulus produced winning and losing outcomes with
equal probabilities, following which the full G/LCT schedule
was implemented which included loss-chasing options (see
Fig. 1). All sessions in the touchscreen chambers were per-
formed in darkness.
The procedure for the G/LCT, adapted from Rogers et al.
(2013), was modified for a touchscreen platform. Two basic
types of trial were presented equally and randomly through
each session: ‘no-choice’ and ‘choice’ (Fig. 1). In a no-choice
trial, which was designed to maintain a high level of
responding, the initiation stimulus was presented to the central
aperture of the touchscreen, touching the stimulus resulted in a
delivery of 22 μl of condensed milk reward in the food mag-
azine. The other 50% of trials were choice trials in which
‘quit’ and ‘gamble’ choice stimuli (‘fan’ and ‘marbles’ pat-
terns, respectively, see Fig. 1) were presented in the left and
right apertures, following a response to the central initiation
stimulus, with the location randomly assigned for each trial.
Choosing the quit stimulus resulted in no reward and a time-
out period of 8 s signalled by illumination of the houselight,
following which a new trial of either no-choice or choice was
initiated. Thus, quitting this initial choice prevented the gam-
bling option and had the potential to bring about a new trial
more quickly. In contrast to a quit response, selecting the
gamble stimulus generated, pseudo-randomly, a reward deliv-
ery of 60 μl reward (a ‘win’) or commenced a time-out period
of 8 s, signalled by illumination of the houselight (a ‘loss’). In
a standard gamble session, the ratio of wins to losses for the
initial decision to gamble was set at 1:1, but this initial gam-
bling choice was also assessed in sessions with different win/
lose ratios (see below).
Collection of the reward after a winning outcome started a
new no-choice or choice trial, but in the case of a losing out-
come, and following the time-out as above, loss-chasing was
assessed by continuing the current trial and offering the op-
portunity for further gamble or quit choices. Here, the animals
were exposed to a series of programmed series of 2, 4 or 8 or
losing outcomes (presented in pseudorandom order) that were
terminated, should an animal continue to gamble and lose for
the entire loss-chasing sequence available, by a winning out-
come (see Supplementary Methods Figure 2). This possibility
was included in the task design to encourage loss-chasing
behaviour in the mice. At any time during a loss-chase se-
quence, the mouse could make a quit response and terminate
these losing runs, receiving a time-out prior to the start of a
new trial. In every trial, the stimuli would remain on the screen
until a response had been made and thus, there were no omit-
ted trials or choices. Thus, the penalty for gambling and losing
(rather than quitting a trial) was to increase the delay to the
next available reward (like in the Rogers et al. 2013 task
design). A session was terminated once the subject had com-
pleted 60 trials or 20 min had elapsed.
Task manipulations
Initial decision to gamble To test the extent to which the
initial decision to gamble was sensitive to the probability
of winning outcomes, the mice were tested with counter-
balanced sequences of sessions with win/lose ratios of
1:4, and 4:1 for the initial gamble. Mice underwent a
sequence of 6 consecutive sessions at each ratio, with a
block of 1:1 win/lose ratio baseline sessions in between
each manipulation.
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Loss-chasing The extent to which the various win/lose
ratios pertaining for the initial gamble influenced the
degree of subsequent loss-chasing behaviour was also
assessed.
Pharmacological manipulations The sensitivity of initial gam-
bling choice and loss-chasing behaviours to pharmacological
challenge were assessed in baseline 1:1 win/lose ratio ses-
sions. This win/lose ratio was selected as it was equivalent
Fig. 1 Schematic of the
touchscreen gambling/loss-
chasing task (G/LCT). The pro-
cedure was adapted from Rogers
et al. (2013) and extended to a
touchscreen platform in mice. A
key modification to the current
task was the introduction of pro-
cedures allowing a more system-
atic evaluation of loss-chasing
behaviour over repeated pro-
grammed losses, allowing the
opportunity for comparisons of
loss-chasing to other components
of gambling behaviour, such as
the initial decision to quit or
gamble. See main text and
Supplementary Methods Figure 2
for further details.
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to the rat task on which this study was based (Rogers et al.
2013), but also as it permitted both increases and decreases in
gambling choices allowing for a non-biased hypothesis for the
possible effects of the different drugs used. 5-HT2CR and 5-
HT1AR were manipulated using SB242084 HCl (0, 0.1, 1,
5 mg/kg) and 8-OH-DPAT HCl (0, 0.03, 0.06, 0.1 mg/kg)
(Cohort 1, N = 20 mice), respectively. Each of these drugs
showing high selectivity for their target receptors (pKi = 9.0
and, pKi = 8.8, for SB242084 and 8-OH-DPAT, respectively
(Kennett et al. 1997; Assié and Koek 2000). The effects of
modafinil (0, 32, 64 mg/kg) were assessed in a separate group
of mice (Cohort 2, N = 20) (all Tocris, UK). Doses of
SB242084 (s.c., administered immediately prior to test), 8-
OH-DPAT (i.p., administered 20 min prior to test) and
modafinil (i.p., 30 min before test) were based on previous
studies (Humby et al. 2013; Fernandes et al. 2013; Rogers
et al. 2013). Drugs were prepared fresh in physiological saline
each day. Each treatment was given using a Latin-square de-
sign, with at least 4 days between each dose; mice were not
tested between the drug administration sessions.
Statistics
Main measures for the G/LCT were the % initial gambling
choice, mean length of a loss-chase sequence, latency to
make an initial gambling choice, proportion loss-chases
ended by a quit response, number of trials started, latency
to initiate a trial, latency to collect the reward and the
numbers of food magazine entries, beam-breaks and
touches to empty apertures of the touchscreen (blank
touches). Scores calculated as percentages were arcsine
transformed, and latencies were square root transformed
prior to analysis. Data were analysed using SPSS (V.20,
IBM Inc., USA) and were first assessed for normality, and
then subjected to t test or ANOVA, if appropriate or
equivalent non-parametric analyses. The comparison of
performance with high (4:1) or low (1:4) win/lose ratios
was analysed by paired two-tailed t tests or Wilcoxon
signed-rank test. These analyses were performed with
the two mouse cohorts combined, but also for compari-
sons between the two groups (Supplementary Results
Figures 4 and 5). The effects of SB242084, 8-OH-DPAT
and modafinil were analysed by separate within-subject
ANOVAs or Friedman tests with a factor of DOSE (vehi-
cle, 0.1, 1, 5 mg/kg, vehicle, 0.03, 0.06, 0.1 mg/kg, and
vehicle, 32 and 64 mg/kg, for each drug, respectively). If
significant, then post hoc pairwise comparisons were per-
formed using Bonferroni or Wilcoxon signed-rank test,
respectively, and adjusted for multiple comparisons.
Criterion level of significance was set at the 0.05 level.
All data are shown as mean ± standard error of the mean
(S.E.M.).
Results
Prior to testing, all 40 mice in the experiment demonstrated
significant preference for the condensed milk reward over
water (c. 80% preference, see Supplementary Results
Figure 1), consistent with previous groups of mice (Humby
et al. 1999, 2005, 2013). Following habituation and shaping
(see Supplementary Results Figure 2), the mice achieved reli-
able and stable performance in the G/LCTwithin 20 sessions
(mean 19.73 ± 0.47 sessions).
C57Bl/6 mice will gamble and chase losses for food
reward
Having learned to touch the screen for reward and shown con-
sistent and stable performance in the baseline version of the G/
LCTwith 1:1win/lose ratio, themiceweremoved on to the task
configuration that included a loss-chasing component. Under
the baseline 1:1 win/lose ratio, for the initial decision to gamble
or quit the animals made more gamble than quit choices (c.70%
gamble choice, see Fig. 2a). As anticipated, the initial decision
to gamble was also sensitive to the probability of gaining re-
ward with more gamble selections (Fig. 2a, t39 = 5.57, p =
0.001, d = 0.33) and quicker responses (Fig. 2b, Z39 = 5.26,
p = 0.001, d = 0.36) in sessions with high win/lose ratios than
low win/lose ratios. These mice also demonstrated loss-chasing
behaviour whereby following the initial choice to gamble and a
loss the animals continued to gamble for reward despite suffer-
ing repeated further losses and associated time-out penalties. As
shown in Fig. 2c, the mean length of consecutive loss-chases
before quitting, under the baseline 1:1 win/lose ratio condition,
was ~ 4 losses (the mice rarely persisted in chasing all 8 losses
available, see Supplementary Results Figure 3a). Loss-chasing
behaviour was sensitive to the prevailing win/lose ratio of the
initial gamble with animals engaging in longer chases in ses-
sions with a high win/lose ratio than in sessions with a low win/
lose ratio (Fig. 2c, Z39 = 2.81, p = 0.005, d = 0.28). As two co-
horts of mice were used in these studies, we have also per-
formed between-cohort comparisons on these data, which dem-
onstrated non-significant results (p > 0.05 for all analyses
(Supplementary Results Figure 4). We also assessed the com-
parison between cohorts using a Bayesian approach (JASP
V0.11, Netherlands) which demonstrated very weak effects
for differences between the two cohorts of mice across all the
measures (BF10 < 1, odds ratio relative to the null hypothesis).
Therefore, both groups of mice showed equivalent responses as
the win/lose ratio was altered. However, we did notice that there
were some changes in performance with the baseline 1:1 win/
lose ratio between the first time of test and on completion of the
win/lose ratio assessments (Supplementary Results Figure 5).
We assessed these differences and found that the propensity to
gamble had significantly increased, and the loss-chase sequence
length reduced for both cohorts of mice; however, we also
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found that these differences remained constant and unchanging
through evaluation of the effects of the drug challenges
(Supplementary Results Figure 5, comparison with vehicle
treatment).
5-HT2CR antagonism with SB242084 reduces
the propensity to gamble without influencing
loss-chasing
The effects of the 5-HT2CR antagonist SB242084 on the initial
decision to gamble and subsequently chase losses are shown
in Fig. 3. The effects of the drug showed dissociations
between these different phases of behaviour. SB242084 at
doses of 0.1, 1 and 5 mg/kg reduced the propensity to make
an initial gamble; that is, the animals showed a clear reduction
in gambling responses and, therefore, a corresponding in-
crease in quitting, under drug (Fig. 3a, main effect of DOSE,
F3,57 = 9.27, p = 0.001, η
2 = 0.99). The effects of SB242084
onwhether to gamble or quit occurred in the absence of effects
on the speed of responding (Fig. 3b, main effect of DOSE,
F3,57 = 2.24, p = 0.09, η
2 = 0.54). The effects of SB242084 on
the initial decision to gamble did not extend to subsequent
loss-chasing, where behaviour was insensitive to drug, insofar
as there were no effects at any dose on the persistence of
Fig. 2 Effects of altering the odds of winning on initial gambling choice
and loss-chasing behaviour in adult C57Bl/6 mice. When the odds of
winning were high, the mice showed a greater initial preference to gamble
(a), were quicker at making this choice (b), and were more likely to loss-
chase (c). Data from the final day of testing at each schedule were used in
the analysis. Data from sessions with a 1:1 win/lose ratio are shown for
illustrative purposes and were not included in the statistical analysis. Data
shows mean ± SE, for both mouse Cohorts combined (N = 40). ** de-
notes p < 0.01 and *** denotes p < 0.001 for the comparison between 4:1
and 1:4 win/ratio tests
Fig. 3 Effects of 5-HT2CR antagonist SB242084 on initial gambling
choice and loss-chasing behaviour in adult C57Bl/6 mice. At all doses
used, SB242084 reduced the initial choice to gamble (a). There were no
effects of SB242084 at any dose on the time taken to make the initial
choice to gamble (b), or on the number of loss-chases made by the mice
(c). For each of these sessions, the win/lose ratio was 1:1. Data shows
mean ± SE, mice from Cohort 1 only (N = 20). *** denotes p < 0.001 for
the comparison with vehicle treatment
Psychopharmacology
gambling in the face of losing runs (Fig. 3c, main effect of
DOSE, F3,57 = 0.29, p = 0.82, η
2 = 0.10). The dissociations in
behaviour were highly specific and occurred in the absence of
drug-induced changes in general components of behaviour for
example, the number of responses/session, latency to start a
trial, locomotor activity and food magazine entries, although
there was a tendency for an increased reward collection laten-
cy with the 5 mg/kg dose (Supplementary Results Figure 3).
5-HT1AR agonism with 8-OH-DPAT has no effects
on the initial decision to gamble but increases
loss-chasing
In contrast to SB242084, 8-OH-DPAT had no statistically sig-
nificant effects on the initial choice to gamble (Fig. 4a). Note
that the main effect of DOSE was close to significance
(F3,57 = 2.86, p = 0.06, η
2 = 0.58), because of elevated rates
of gamble responses at the highest dose used, of 0.1 mg/kg;
however, this dose was also associated with major disruptions
in general components of behaviour, including marked
slowing of choice responding (Fig. 4b, main effect of
DOSE, F3,57 = 11.20, p = 0.001, η
2 = 0.99) and a decline in
the overall number of trials started in a session from ~ 60
under vehicle conditions to ~ 40 (see Supplementary Results
Figure 4). There was evidence of specific effects of 8-OH-
DPAT on loss-chasing behaviour. These effects were manifest
as an increase in consecutive loss-chases at the lowest,
0.03 mg/kg, dose of drug (Fig. 4c, main effect of DOSE,
F3,57 = 4.48, p = 0.01, η
2 = 0.86, confirmed by post hoc com-
parison: p < 0.05 for 0.03 mg/kg dose to all other doses) in the
absence of generalised effects on other behavioural measures
(Supplementary Results Figure 4).
Modafinil reduces both the propensity to gamble
and loss-chasing behaviour
Modafinil reduced initial choices to gamble, thereby increas-
ing quitting behaviour (Fig. 5a, main effect of DOSE, F2,38 =
4.28, p = 0.02, η2 = 0.18); post hoc comparisons showing that
choices to start gambling at the 32 mg/kg dose were signifi-
cantly diminished compared to vehicle (p = 0.035), but not
with the 64 mg/kg dose (p = 0.84). The effects of the
32 mg/kg dose of modafinil in reducing gambling choices
were not associated with any marked effects on the speed of
responding; however, the 64 mg/kg dose reduced speed of
responding (Fig. 5b, main effect of DOSE, F2,38 = 4.63, p =
0.02, η2 = 0.18; comparisons of vehicle and 32 mg/kg: p =
0.80, and vehicle and 64 mg/kg p = 0.045). Modafinil reduced
the extent of subsequent loss-chasing but again only at the
lower 32 mg/kg dose (Fig. 5c, main effect of DOSE, F2,38 =
7.14, p = 0.002, η2 = 0.27, post hoc comparisons of 32 mg/kg
dose with vehicle and 64 mg/kg of p = 0.03 and p = 0.001,
respectively). Neither dose was associated with any marked
change in general features of behaviour save a slight tendency
for the overall number of trials started to increase at the highest
dose (Supplementary Results Figure 5).
Discussion
We have used a novel touchscreen-based paradigm in mice to
investigate gambling behaviours. We established that hungry
mice will gamble and loss-chase to achieve food reward, with
the possible penalty of losing as increased delay to the next
available reward. The mice were sensitive to the relative
Fig. 4 Effects of the 5-HT1AR agonist 8-OH-DPAT on initial gambling
and loss-chasing behaviour in adult C57Bl/6Ola mice. 8-OH-DPAT did
not significantly affect the initial choice of the mice to gamble (a), but
increased the time taken to make this choice, although this was only at the
0.1 mg/kg dose used (b). Loss-chasing was influenced by 8-OH-DPAT,
with a significant increase from vehicle that was specific to the lowest
0.03 mg/kg dose of the drug (c). For each of these sessions, the win/lose
ratio was 1:1. Data shows mean ± SE, mice from Cohort 1 only (N = 20).
* denotes p < 0.05 and ** p < 0.01 for comparison with vehicle treatment,
respectively
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probabilities of winning/losing outcomes, as seen in humans
and other species mice, by increased gambling and loss-
chasing when winning was more likely or quitting gambling
when winning was less likely. We found evidence for the
existence of dissociable effects of serotonergic drugs and
modafinil on different aspects of gambling behaviour.
Antagonism of 5-HT2CR with SB242084, whilst decreasing
the likelihood of C57Bl/6 mice to make an initial gambling
choice, had no effects on the persistence of subsequent loss-
chasing behaviours. In contrast, 5-HT1AR agonism, with low
dose 8-OH-DPAT, had no effects on the likelihood of subjects
choosing to initiate gambling, but once they had gambled
tended to increase the subsequent loss-chasing behaviours.
Modafinil at a dose of 32mg/kg decreased both the propensity
to engage in gambling and reduced loss-chasing. Our data are
consistent with the suggestion that serotonin receptor systems
may play dissociable roles in starting and then sustaining gam-
bling responses in the face of continued losing outcomes
(Campbell-Meiklejohn et al. 2011; Rogers et al. 2013); addi-
tionally, they indicate the efficacy of modafinil, a putative
cognitive enhancer, to modify gambling behaviours.
Human studies have attempted to parse components of
gambling behaviours and there is evidence for the existence
of dissociable neural systems and pharmacological substrates
underlying, for example, the decision to chase losses or quit
(Campbell-Meiklejohn et al. 2008, 2011 and 2012). However,
to our knowledge, there have been no explicit comparisons of
the pharmacological mechanisms of initial decisions to
gamble/quit and subsequent loss-chasing behaviour in either
un-drugged or drug treated subjects. Behavioural economic
perspectives, such as Prospect Theory (Kahneman and
Tversky 1979; Kahneman and Tversky 2000), posit that
within-session loss-chasing behaviour persists because in the
case of typical human gambling behaviour, accumulating
monetary losses generate only diminishing marginal reduc-
tions in subjective value (relative to gamblers’ current purse),
prompting the persistence of risk-seeking choices (Campbell-
Meiklejohn et al. 2008). According to this view, initial deci-
sions to gamble are distinguished by the potential for greater
reductions in subjective value compared to subsequent deci-
sions to continue gambling. Additionally, loss-chasing may
also be contributed to by a form of behavioural momentum,
manifest as the persistence of choices previously but not cur-
rently rewarded in the same context (Kahneman and Tversky
1979; Nevin 2002). Irrespective of these theoretical specula-
tions regarding the psychological underpinnings of gambling
behaviours, the pharmacological data presented here suggest
that 5-HT2CR and 5-HT1AR activity modulate risky choices to
varying extents between the initial decision and subsequent
loss-chasing.
Our findings add to the increasing evidence for serotoner-
gic neurotransmitter influences on gambling behaviours as
demonstrated in both human and animal model studies
(Zeeb et al. 2009; Campbell-Meiklejohn et al. 2011; Rogers
et al. 2013). A novel finding was the efficacy of SB242084 to
alter gambling behaviour by reducing the propensity to make
an initial gamble (increased quitting) with no effects on loss-
chasing. Quitting the initial gambling choice, and receiving a
time-out, could be interpreted as choosing the safer option
which was more guaranteed to provide reward quicker than
electing to gamble which induced further delays. Changes in
5-HT2CR function, specifically hypersensitivity, have been
suggested to occur in pathological gamblers (Conversano
et al. 2012). Hence, the data with SB242084 are consistent
Fig. 5 Effects of modafinil on gambling and loss-chasing behaviour in
adult C57Bl/6 mice. Modafinil reduced the initial decision to gamble by
the mice at the 32 mg/kg dose with no significant effects of the higher
64mg/kg dose (a). Modafinil reduced the time taken tomake the decision
to gamble, effects that reached significance at the 64 mg/kg dose but not
32mk/kg dose (b). Loss-chasingwas also influenced bymodafinil, with a
significant reduction in behaviour from vehicle at 32 mg/kg but not
64 mg/kg (c). For each of these sessions, the win/lose ratio was 1:1.
Data shows mean ± SE, mice from Cohort 2 (N = 20). * denotes
p < 0.05 for the comparison with vehicle treatment
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with human work; however, the precise psychological and
brain mechanisms by which 5-HT2CR antagonism impacts
on dissociable aspects of gambling behaviour are unknown
but could be centred in the prefrontal cortex where these re-
ceptors are expressed (Pompeiano et al. 1994). One possible,
hypothesis may be the involvement of cortical 5-HT2CR in top
down processing and control of model-based and striatal
model-free mechanisms for behavioural choice (Daw et al.
2005; Russek et al. 2017; Kim et al. 2019). In the current task,
5-HT2CR antagonism could influence the dissociation be-
tween these systems, via modulating striatal dopamine
(Seymour et al. 2012) in the drive to move from initially
gambling (and losing) to loss-chasing to pursue a potential
win. However, previous studies have demonstrated the effects
of SB242084 on response control and selection are complex,
with evidence for both decreased (Humby et al. 2013) and
increased impulsivity in control of choices (Winstanley et al.
2004; Fletcher et al. 2007; Robinson et al. 2008; Paterson et al.
2012). Acute activation of 5-HT2CR inhibits feeding (Clifton
and Kennett 2006), and various 5-HT2CR agonists are current-
ly registered to treat obesity (Palacios et al. 2017). SB242084
will reduce the anorectic effects of d-fenfluramine, mCPP or
novelty-induced hypophagia, but does not affect food intake
when administered alone (Vickers et al. 2001; Hewitt et al.
2002; Nahata et al. 2013). Thus, the findings observed here
are unlikely to be a due to effects of SB242084 on feeding
mechanisms or drive to achieve reward. Nonetheless, 5-
HT2CRs are expressed in brain circuitries with established
roles in mediating response control and responses to reward
(Barnes and Sharp 1999; Chagraoui et al. 2016) and further
investigation of these psychological functions in the context
of explaining the putative specificity of 5-HT2CR blockade on
gambling behaviours is warranted.
In previous work using rat models, 8-OH-DPAT has been
shown to reduce loss-chasing behaviour (Rogers et al. 2013).
Using the same dose range in the current mouse task, we
observed no significant effects on the initial decision to gam-
ble but instead an increase in loss-chasing that was confined to
the lowest 0.03 mg/kg dose consistent with a pre-synaptic
effect of 5-HT1AR agonism (i.e. reduced 5-HT release,
Sharp et al. 1989). There are several possible reasons for the
contrasting effects of 8-OH-DPAT on loss-chasing seen here
and in Rogers et al. (2013) work, which may include species
differences but also a task difference which may be interacting
with reduced 5-HT release. Specifically, in the present study,
the subjects could endure up to 8 successive losses with the
possibility of reward at the end, whereas in the rat task loss-
chasing was programmed to curtail following only 2 extra
gambles followed by a punishment (Rogers et al. 2013).
This difference may have increased the propensity to loss-
chase by the mice as a result of increased behavioural momen-
tum, linked to the fact that increased persistence could result in
reward, or as an effort to overcome the potentially greater
number of negative outcomes (represented as accumulating
delay to the next available reward) present in our mouse task
(Nevin 2002). A further hypothesis is related to the involve-
ment of 5-HT mechanisms in mediating feeding (Palacios
et al. 2017), where it could be that increased loss-chasing
reflected a drive to seek food by continued gambling.
Although 8-OH-DPAT treatment increases feeding in non-
food deprived rodents (Shepherd and Rogers 1990;
Ebenezer and Surujbally 2007), it may lead to decreased or
no changes in consumption of palatable foodstuffs (e.g. con-
densed milk rewards, as used in the current study) at doses
comparable with those used here (Dourish et al. 1988;
Swiergiel & Dunn 2000; Ebenezer and Tite 2003), thus a
feeding-related hypothesis for our findings seems unlikely.
There have been suggestions that putative ‘cognition en-
hancers’ such as modafinil may be of use in pathological gam-
bling (Łabuzek et al. 2014; Pettorruso et al. 2014). We tested
the effects of modafinil in our model and found dose-sensitive
reductions in both initial gambling choice and subsequent
loss-chasing behaviour. In humans, modafinil has complex
effects on gambling behaviours, with dissociable effects in
problem gamblers that are dependent on high/low impulsivity
traits, such as reducing the desire to gamble, the salience of
gambling stimuli (such as gambling-related words) and criti-
cally, making risky choices (Zack and Poulos 2004; Smart
et al. 2013). In the present work, we did not divide our exper-
imental group into subgroups based on measures of individual
impulsivity but found consistent effects of modafinil in reduc-
ing gambling choices. The psychological substrates of these
effects from the data to hand remain unknown but the most
prominent and robust effect of modafinil seems to be on gen-
eral arousal and attention, rather than any specific cognitive
process, via cortical mechanisms (Scoriels et al. 2013; Smart
et al. 2013). On that basis, it might be speculated that
modafinil could impact on multiple facets of loss-chasing be-
haviour, including, as we demonstrate here, the control of
impulses to gamble in the first place to the control of persistent
gambling in the face of repeated losses.
The precise neurobiological mechanism(s) of action of
modafinil are, at present, also obscure. Modafinil does not
appear to act as a monoamine releaser, as is the case for
amphetamine-based stimulants, but has diverse effects on
multiple neurotransmitter and modulatory systems
encompassing, α-adrenoreceptors, GABA, orexin, dopamine
and glutamate systems (Ballon and Feifel 2006), many of
which have been implicated in gambling, and underlying psy-
chologies mediating risk and decisionmaking (Potenza 2013).
For example, noradrenaline and orexins can affect motivation,
arousal and decision-making (Chen et al. 2015; Quintero
Garzola 2019) and decreased sensi t iv i ty of α2-
adrenoreceptors has been reported in pathological gamblers
(Quintero Garzola 2019), furthermore, clonidine, an α2-
adrenoreceptor agonist decreased risky choice by decreasing
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reward sensitivity responding in a rat risk-taking task (Montes
et al. 2015). Infusions of GABAA and GABAB receptor ag-
onists into the prelimbic or infralimbic regions of the frontal
cortex affect decision-making in a rat gambling task (Zeeb
et al. 2015), and ketamine and MK801 NMDA receptor an-
tagonists, affecting glutamate transmission, also influence de-
cision making in probabilistic discounting tasks (Yates 2019).
Clearly, more work is required to specify the precise brain
mechanisms mediating the effects of modafinil on gambling
behaviours.
In conclusion, we have developed a novel touchscreen as-
say to examine dissociable aspects of within-session gambling
behaviour in mice. Mice demonstrated the expected patterns
of behaviour when the odds for winning were altered resem-
bling gambling behaviours seen in humans and other model
species. With mice still ahead of rats as the main tractable
genetic model for behavioural and neurobiological research
(Muñoz-Fuentes et al. 2018), there is still a need for the de-
velopment of novel methods of evaluating ‘normal’ mouse
behaviour as a means to understand atypical patterns of be-
haviour following genetic or pharmacological manipulation.
Thus, developing tasks such as the G/LCT will enable re-
searchers to investigate a range of mechanisms related to path-
ological gambling (and response control) using mice as a
model organism. We probed neurobiological mechanisms
using pharmacological manipulations of the serotonergic sys-
tem, specifically 5-HT2C and 5-HT1A receptors, and the puta-
tive cognition enhancer modafinil. The drugs had different
effects on gambling behaviours providing evidence consistent
with there being different brain mechanisms and systems op-
erating to influence an initial decision to gamble and subse-
quent decisions to continue gambling in the face of repeated
losses. Loss-chasing behaviour is a key component of prob-
lem gambling; hence, this work may have utility in modelling
the complex psychological and neurobiological underpin-
nings of pathological gambling.
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